Endocrine Abstracts

Introduction: Obesity, a chronic disease, is recognised as a major public health problem. In 2023, the National Institute for Health and Care Excellence (NICE) recommended semaglutide, a weekly glucagon-like peptide-1 (GLP-1) agonist, as a pharmacological option for weight management. This case series aims to evaluate the real-world effectiveness and safety profile of semaglutide therapy for weight loss.Methods: Retrospe...

Introduction: The prevalence of obesity, a chronic disease with significant morbidity, has rapidly increased in recent decades. Semaglutide, an injectable glucagon-like peptide-1 agonist, has gained global popularity after its approval for weight management in 2021. All studies have reported marked variability in semaglutide response, with a small proportion of patients (10-16%) showing inadequate response. Data about the predictors of poor response to semaglutide for weight l...